Evidence map›Paper›PMID 23866683›Full record

ArticleJournal of neuroinflammation2013

Diverse activation of microglia by chemokine (C-C motif) ligand 2 overexpression in brain.

Maj-Linda B Selenica, Jennifer A Alvarez, Kevin R Nash, Daniel C Lee, Chuanhai Cao, Xiaoyang Lin, Patrick Reid, Peter R Mouton, Dave Morgan, Marcia N Gordon

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 2 pooled it
7.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Protective effects of GPR37FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019
    Article
  20. GABAPsychopharmacology · 2019
    Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Maj-Linda B SelenicaDepartment of Molecular Pharmacology & Physiology, Byrd Alzheimer Institute, University of South Florida, Tampa, FL, USA.
Jennifer A Alvarez
Kevin R Nash
Daniel C Lee
Chuanhai Cao
Xiaoyang Lin
Patrick Reid
Peter R Mouton
Dave Morgan
Marcia N Gordon
University of South Florida · USUSF Health Byrd Alzheimer's Institute · US

Funding

PREDICTORS OF THE RATE OF COGNITIVE DECLINE IN ELDERLY SUBJECTSP50AG025711 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI POTTER, HUNTINGTON · 2005 to 2010
$8.2M
TRANSGENIC MICE, INFLAMMATION &THE ALZHEIMER PHENOTYPER01AG015490 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI GORDON, MARCIA N · 1999 to 2012
$3.3M
NIA NIH HHS AG15490NIA NIH HHS AG25711
6 · The paper itself

Abstract

backgroundThe chemokine (C-C motif) ligand 2 (CCL2) is a monocyte chemoattractant protein that mediates macrophage recruitment and migration during peripheral and central nervous system (CNS) inflammation.

methodsTo determine the impact of CCL2 in inflammation in vivo and to elucidate the CCL2-induced polarization of activated brain microglia, we delivered CCL2 into the brains of wild-type mice via recombinant adeno-associated virus serotype 9 (rAAV-9) driven by the chicken β-actin promoter. We measured microglial activation using histological and chemical measurement and recruitment of monocytes using histology and flow cytometry.

resultsThe overexpression of CCL2 in the CNS induced significant activation of brain resident microglia. CD45 and major histocompatibility complex class II immunoreactivity significantly increased at the sites of CCL2 administration. Histological characterization of the microglial phenotype revealed the elevation of "classically activated" microglial markers, such as calgranulin B and IL-1β, as well as markers associated with "alternative activation" of microglia, including YM1 and arginase 1. The protein expression profile in the hippocampus demonstrated markedly increased levels of IL-6, GM-CSF and eotaxin (CCL-11) in response to CCL2, but no changes in the levels of other cytokines, including TNF-α and IFN-γ. Moreover, real-time PCR analysis confirmed increases in mRNA levels of gene transcripts associated with neuroinflammation following CCL2 overexpression. Finally, we investigated the chemotactic properties of CCL2 in vivo by performing adoptive transfer of bone marrow-derived cells (BMDCs) isolated from donor mice that ubiquitously expressed green fluorescent protein. Flow cytometry and histological analyses indicated that BMDCs extravasated into brain parenchyma and colabeled with microglial markers.

conclusionTaken together, our results suggest that CCL2 strongly activates resident microglia in the brain. Both pro- and anti-inflammatory activation of microglia were prominent, with no bias toward the M1 or M2 phenotype in the activated cells. As expected, CCL2 overexpression actively recruited circulating monocytes into the CNS. Thus, CCL2 expression in mouse brain induces microglial activation and represents an efficient method for recruitment of peripheral macrophages.

Indexed as

Adoptive TransferAnimalsBone Marrow CellsBrain ChemistryCell MovementChemokine CCL2CytokinesDependovirusGene ExpressionGenetic VectorsGene Transfer TechniquesGreen Fluorescent ProteinsHumansImage Processing, Computer-AssistedImmunohistochemistryMacrophage ActivationChemokine CCL2CytokinesGreen Fluorescent Proteins

Identifiers

PMID23866683
PMCPMC3726363
OpenAlexW2146795905

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.